SEC Tracker
Get the app

Possible new RNAZ shares

RNAZDilution

Known so far: no new shares from the prospectus covers read · shelf room about $2.2M · not yet read: warrants, converts, options, ATM.

Shelf room

  • Room today about $2.2M
  • One third of float $2.2M ($6.5M float, Jun 30, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $2.2M on the S-3 of Apr 30, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $6.5M public float stated as of Jun 30, 2025, $2.2M, nothing sold off it in the last 12 months. Sources: S-3 Apr 30, 2026, effective May 19, 2026 · public float, as of Jun 30, 2025.

What could become new Transcode Therapeutics (RNAZ) shares, from its 10-Q, 10-K, S-1 or 424B filings.

Read so far: the cover share count (16.9M shares, +1931% from 834K on Aug 8, 2025). Not read yet: warrants, convertible notes, options and RSUs and an ATM program. Read them on EDGAR: the latest 10-Q · S-1 registration filings.

Shares outstanding

16.9M

Nov 2024 to Aug 2026: from 617K to 16.9M. Adjusted for the 1-for-28 reverse split by Aug 8, 2025: each earlier count is divided by the ratio of every split after it.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.